Collection
Reading the evidence
Biological-age tests, fish oil and fasting show why the measured outcome matters. Three full articles trace the distance between an interesting signal and a demonstrated benefit.
- When your biological-age number moves, what moved?Repeating a laboratory result is not the same as measuring a stable trait
- Fish oil reached the brain. The hoped-for benefit did not follow.A two-year DHA trial separates biological activity from clinical benefit
- Fasting and muscle: the unanswered part of the weight-loss storySmall short-term differences in lean mass do not settle long-term function
26 OCTOBER 2026 · ONLINE UPDATE
Nicotinamide riboside did not improve early Parkinson’s outcomes
The NOPARK article in The Arising’s October 25 edition reports a randomized, double-blind trial of 410 people with early Parkinson’s disease. Nicotinamide riboside, 500 mg twice daily for 52 weeks, did not improve clinical outcomes compared with placebo; 393 participants were included in the primary analysis.
The primary symptom-score difference was 2.72 points in favor of placebo (95% confidence interval, 0.47–4.98), below the trial’s stated 5.2-point threshold for clinically important worsening. This result concerns one compound, dose, disease and duration. It does not establish a benefit for healthy aging or settle every question about NAD biology.
Serious adverse events occurred in 17 of 205 participants receiving nicotinamide riboside and 29 of 205 receiving placebo in the safety analysis. These counts alone do not establish that the supplement is safer.
Primary study · published October 8, 2026 ↗ · Trial registry ↗
This online update connects Monday’s discussion to the collection. It is additional reading, not part of the October 25 PDF’s three articles. Review depth: primary abstract and selected registry fields; the full paper, supplements and complete funding and conflict disclosures have not been appraised here.
Does it help patients?
A November 2 Arising discussion uses cerebral embolic protection during valve replacement as a worked example of the difference between a plausible mechanism and patient-outcome evidence. The research appeared online in May 2026. The linked dispatch preserves the uncertainties and review limits. This reading connection does not revise the dated booklet PDF.